Potential New Approach to Covid-19 Prevention
Recent research suggests a promising method to prevent Covid-19. A team from the University of Saarland in Germany conducted a clinical trial revealing that nasal sprays may lower the risk of coronavirus infection by about two-thirds.
This Phase 2 study, published in Jama Internal Medicine, took place at Saarland University Hospital over a period from March 2023 to July 2024. A total of 450 healthy adults participated, randomly assigned to either an azelastine nasal spray or a placebo, administered three times daily for 56 days.
Throughout the study, participants underwent SARS-COV-2 rapid antigen tests twice each week to check for infections. If any displayed symptoms but tested negative, they were given additional PCR tests for respiratory viruses.
Among those who received the azelastine nasal spray, only 2.2% were confirmed to have COVID infections, which was significantly lower than the 6.7% seen in the placebo group.
The research also pointed out that people using azelastine experienced an extended pre-infection period. These patients showed a decreased incidence of symptomatic infections caught in PCR tests as well as fewer confirmed infections from common cold viruses.
The researchers noted, “In this single-centered trial, azelastine nasal spray was associated with a reduced risk of SARS-COV-2 respiratory infection.” A release from the University of Saarland mentioned the spray is often prescribed for hay fever and has previously been claimed to have antiviral effects against both Covid and other respiratory viruses.
Professor Robert Balz, who leads internal medicine at Saarland University Medical Center, highlighted that the study demonstrated azelastine’s effects in real-world settings.
“Azelastine nasal sprays may offer a convenient, additional preventive option to supplement current protective measures, especially for more vulnerable populations,” he added.
The findings open the door for further investigation; larger multicenter trials are suggested to assess azelastine’s effectiveness against other respiratory pathogens.
